Thymidine labelling index as prognostic factor in resected non-small cell lung cancer

Angela Alama, Massimo Costantini, Lazzaro Repetto, P. F. Conte, Jacopo Serrano, Angelo Nicolin, Federica Barbieri, Andrea Ardizzoni, Paolo Bruzzi

Research output: Contribution to journalArticle

Abstract

To assess the prognostic value of tumor proliferative activity, 89 patients with operable non-small cell lung cancer were studied. Tumor samples were obtained during surgery and cell kinetics were analyzed by the in vitro thymidine labelling index (TLI). The overall median TLI (2.9) was used to identify two subsets of patients with high and low proliferating tumors. In univariate analysis survival was significantly longer in patients with lower TLI (P = 0.047) and with stage I-II (P = 0.003) and T1-T2 tumors (P = 0.043). In multivariate analysis, stage was the most important prognostic parameter (P = 0.004). The risk of death for patients with TLI higher than 2.9 was increased (hazard ratio = 2.01, CI = 0.96-4.27).

Original languageEnglish
Pages (from-to)622-625
Number of pages4
JournalEuropean Journal of Cancer and Clinical Oncology
Volume26
Issue number5
DOIs
Publication statusPublished - 1990

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Thymidine labelling index as prognostic factor in resected non-small cell lung cancer'. Together they form a unique fingerprint.

  • Cite this